Eli Lilly and Company EV/EBITDA
Data as of June 01, 2026
EV/EBITDA
28.26
Enterprise Value
$1.02T
EBITDA (TTM)
$36.22B
Sector
Healthcare
How It's Calculated
28.26 = $1.02T ÷ $36.22B
What This Means
Eli Lilly and Company's EV/EBITDA of 28.3 is elevated, which can reflect growth expectations, scarce assets, or cyclical EBITDA.
About Eli Lilly and Company
Eli Lilly and Company (LLY) operates in the Healthcare sector, specifically in Drug Manufacturers - General. With a market capitalization of about $985.37B, it ranks as a mega-cap stock — one of the largest publicly traded companies.
Shares recently traded near $1105.00, within a 52-week range of $623.78 to $1149.10 (-3.8% from the high, +77.1% from the low). Beta of 0.48 indicates relatively lower volatility versus the market.
Trailing profit margin is about 35.0%, signaling a strong profit margin relative to many peers.
Understanding This Metric
EV/EBITDA is widely used when comparing companies with different debt loads because enterprise value includes net debt while EBITDA approximates operating cash earnings power. For Eli Lilly and Company, the ratio should be read with growth, capex needs, and cycle position in Healthcare. Pair EV/EBITDA with free cash flow yield and net debt metrics before drawing conclusions — especially when EBITDA is depressed or boosted by one-time items.
Using This Number in Practice
Near 28.26x EV/EBITDA, Eli Lilly and Company (LLY) carries an elevated EV/EBITDA multiple that may embed growth expectations or scarcity within its peer set. Enterprise value of about $1.02T and EBITDA near $36.22B form the ratio — adjust for one-time items before treating the headline multiple as comparable.
Credit and LBO workflows often sort names on EV/EBITDA before drilling into free cash flow and maintenance capex. Pair this view with the EV/EBITDA calculator and the LLY metrics hub for related valuation pages.
Sector Comparison
Among Healthcare names on our S&P 100 coverage, Eli Lilly and Company's EV/EBITDA of 28.26 can be compared with peers such as JNJ (16.76), UNH (18.61), MRK (11.41). Sector context helps interpretation, but each company's growth profile and balance sheet differ — use multiple metrics before drawing conclusions. View all Healthcare stocks.
Key Takeaways
- LLY is grouped in the Healthcare sector for peer comparisons.
- Recent beta of 0.48 suggests lower-than-market price sensitivity.
- Trailing profit margin of 35.0% provides context for how much earnings support the headline multiple.
Related Tools & Guides
Explore calculators and guides connected to this metric, or view all metrics for LLY.
Other LLY Metrics
Frequently Asked Questions
What is LLY's EV/EBITDA?
EV/EBITDA compares enterprise value to operating earnings before interest, taxes, depreciation, and amortization. Eli Lilly and Company's ratio is about 28.26 — common for comparing leveraged companies in Healthcare.
Is 28.26 high or low vs peers?
Among Healthcare peers (e.g. TMO (19.75), UNH (18.61), DHR (18.06)), LLY's 28.26 should be read with growth, capex, and debt levels.
When is EV/EBITDA misleading?
EBITDA ignores capex, working capital, and stock-based comp; negative or tiny EBITDA makes the ratio meaningless. Cross-check with free cash flow and net debt.
Calculate the ev/ebitda for any stock with our free calculator.
Open EV/EBITDA Calculator →